New 5-Quart Presentation of Triamulox™ Liquid Concentrate Eases Medication Storage, Handling for Pork Producers

Economical Solution for Managing Pneumonia, Dysentery

DURHAM, N.C., September 10, 2018 — A water-soluble antibiotic used widely in the pork industry to treat herds for respiratory and enteric disease is now available in a five-quart bottle for easier storage and handling with less waste.

Marketed by Zoetis, Triamulox™ Liquid Concentrate (tiamulin hydrogen fumarate) may be added to pigs’ drinking water to treat pneumonia caused by Actinobacillus pleuropneumoniae (APP) and swine dysentery caused by Brachyspira hyodysenteriae. Triamulox is a bioequivalent to Denagard® LC.

“When pigs are sick and go off feed, it’s important to treat them quickly and efficiently with an effective antibiotic — not only to control infection and protect the welfare of the herd, but also to prevent losses in performance,” said Eva Jablonski, DVM, a technical services veterinarian for Zoetis.

“The new five-quart presentation of Triamulox meets this need while also helping producers reduce costs and cut waste.”
Pigs of all sizes
While Triamulox is approved for use in pigs of all sizes, Dr. Jablonski said it is used primarily in growing pigs. The new five-quart bottle of Triamulox contains enough active ingredient to produce up to 2,560 gallons of water medication. That’s enough to treat 1,330 125-pound pigs for swine dysentery (3.5 mg/lb bodyweight) or 443 125-pound pigs for APP (10.5 mg/lb bodyweight).

Because tiamulin, the active ingredient in Triamulox, is not considered medically important to humans by the Food and Drug Administration, the product may be used without a veterinary prescription. However, Zoetis urges producers to work closely with their veterinarians on all antibiotic decisions. 

Zoetis will continue to market the one-quart size of Triamulox, which the company launched in 2016.

To learn more about Triamulox and other tools for responsible antibiotic use, contact your Zoetis representative or visit

About Zoetis
Zoetis  (NYSE: ZTS) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2017, the company generated annual revenue of $5.3 billion with approximately 9,000 employees. For more information, visit

For further information, contact:
Julie Groce
Zoetis US LLC

Joseph Feeks 
PR Works



Mon–Fri, 8:30am–6:30pm ET

This site is intended for U.S. Animal Healthcare Professionals. The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. ©2022 Zoetis Services LLC. All rights reserved.